Table 4.
The single- and combined- synergizing, or resistance-inducing effects of Navitoclax on cellular apoptosis
| Cancer | Cell Type | Combined | Apoptosis | Ref |
|---|---|---|---|---|
| AML | Primary cells | dasatinib | – | [141] |
| AML/ALL | Jurkat, Molt-4 | wogonin | synergized | [142] |
| Cervical | SiHa, CaSki | A-1210477 | synergized | [139] |
| CRC | HCT116, DLD1, SW48, HT29, HCT-8 | apigenin | synergized | [143] |
| CRC, Liver | Huh7, HepG2, BEL7402, HCT116, DLD1, AGS | sorafenib | synergized | [144] |
| CRC/Melanoma | Colo-205 | AZD6244 resistance | – | [145] |
| Esophageal | SKGT-4, KATO-TN, YES-6 | fluorouracil | synergized | [146] |
| Esophageal | EC109, HKESC-2, CaES-17 | -single- | – | [147] |
| HNSCC | HN12 | fenretinide | synergized | [148] |
| Liver | Huh7 | TRAIL resistance | – | [149] |
| Lung | H1650 and H1975 | src-inhibitors | synergized | [150] |
| Non-small cell lung | LC2, PC10 | cisplatin | synergized | [151] |
| Small cell lung | H209 | vorinostat | synergized | [152] |
| Lymphoma | DoHH-2 and SuDHL-4 | rapamycin | – | [153] |
| Neuroblastoma | SH-SY5Y and CHLA-119 | norcantharidin | synergized | [154] |
| Prostate | LNCaP and PC3 | paclitaxel | synergized | [155] |
| Prostate | PC3, C4–2B, C4–2, DU145 | MLN2238 | synergized | [156] |
| Ovarian | Numerous | paclitaxel/gemcitabine | synergized | [157] |
| Liver, Prostate, Cervical, CRC, NSCLC | Hep3B, PC3, HCT-116, SW480, and SW620, H1299, SK-BR-3, HeLa | metformin | synergized | [158] |
The cancer types are highlighted in bold (left column), the evaluation of single therapy alone is highlighted by -single-, non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia, ALL Acute Lymphoblastic Lymphoma, CRC Colorectal cancer, HNSCC Head and Neck Squamous Cell Carcinoma, NSCLC Non-small cell lung cancer